Patients aged 10 to 17 years who are prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are more likely to have ...

Patients aged 10 to 17 years who are prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are more likely to have ...

It may not sound surprising that treating obesity in adolescents and teens may have positive mental health impacts, but ...

Weight-loss supplements are rebranding as “GLP-1 boosters.” They’re nothing like Ozempic. If you had come across the ...

This is just a sneak peek at the thousands of consumer insights available to CivicScience clients. Discover more data. The ...

Baby Boomers looking to put new money to work may wish to check out the broader basket of dividend stocks while interest ...

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) given to adolescents with obesity was associated with a one-third ...

The FDA yesterday the approval of Novocure’s Optune device to include the treatment of metastatic non-small cell lung cancer.

Researchers found that 1.4% of adolescents on weight loss medications had a suicide attempt or ideation, compared with 2.3% of children who weren’t taking the medicines. Separately, anxiety is found ...

Neurogastrx believes its drug could treat one of the most troublesome side effects of one of the industry's biggest blockbusters. On Wednesday, the Boston-area biotech said that its experimental drug ...

A review of the medical records of thousands of adolescents treated for obesity found that kids who received the GLP-1 ...

Tirzepatide, a cutting-edge medication initially approved for the treatment of type 2 diabetes, has shown remarkable potential in facilitating significant weight loss. This dual GIP and GLP-1 receptor ...